Hyperdynamic circulation in cirrhosis: a role for nitric oxide? - PubMed (original) (raw)
Hyperdynamic circulation in cirrhosis: a role for nitric oxide?
P Vallance et al. Lancet. 1991.
Abstract
Hypotension, low systemic vascular resistance, and a reduced sensitivity to vasoconstrictors are features of cirrhosis. These cardiovascular changes might be the result of increased synthesis of a vasodilator. Nitric oxide (NO), a potent vasodilator, is synthesised in and released from peripheral blood-vessels in man. Studies in animals indicate that bacterial endotoxin and cytokines induce NO synthase expression in vessel walls, with sustained NO release and consequent hypotension. Endotoxaemia is a common feature of cirrhosis; persistent induction of NO synthase may account for the associated haemodynamic changes.
Similar articles
- Increased nitric oxide synthesis and inducible nitric oxide synthase expression in patients with alcoholic and non-alcoholic liver cirrhosis.
Sánchez-Rodríguez A, Criado M, Rodríguez-López AM, Esteller A, Martín de Arriba A, López-Novoa JM. Sánchez-Rodríguez A, et al. Clin Sci (Lond). 1998 Jun;94(6):637-43. doi: 10.1042/cs0940637. Clin Sci (Lond). 1998. PMID: 9854462 - Hemodynamic alterations in liver cirrhosis.
La Villa G, Gentilini P. La Villa G, et al. Mol Aspects Med. 2008 Feb-Apr;29(1-2):112-8. doi: 10.1016/j.mam.2007.09.010. Epub 2007 Oct 24. Mol Aspects Med. 2008. PMID: 18177931 Review. - Circulating nitric oxide products do not solely reflect nitric oxide release in cirrhosis and portal hypertension.
Afzelius P, Bazeghi N, Bie P, Bendtsen F, Vestbo J, Møller S. Afzelius P, et al. Liver Int. 2011 Oct;31(9):1381-7. doi: 10.1111/j.1478-3231.2011.02576.x. Epub 2011 Jul 5. Liver Int. 2011. PMID: 21745317 - Inhibition of interleukin-1-alpha-induced nitric oxide synthase in vascular smooth muscle and full reversal of interleukin-1-alpha-induced hypotension by N omega-amino-L-arginine.
Kilbourn RG, Gross SS, Lodato RF, Adams J, Levi R, Miller LL, Lachman LB, Griffith OW. Kilbourn RG, et al. J Natl Cancer Inst. 1992 Jul 1;84(13):1008-16. doi: 10.1093/jnci/84.13.1008. J Natl Cancer Inst. 1992. PMID: 1376778 - The role of nitric oxide in portal hypertensive systemic and portal vascular pathology.
Hartleb M, Michielsen PP, Dziurkowska-Marek A. Hartleb M, et al. Acta Gastroenterol Belg. 1997 Jul-Sep;60(3):222-32. Acta Gastroenterol Belg. 1997. PMID: 9396180 Review.
Cited by
- Nitric oxide and portal hypertension.
González-Abraldes J, García-Pagán JC, Bosch J. González-Abraldes J, et al. Metab Brain Dis. 2002 Dec;17(4):311-24. doi: 10.1023/a:1021957818240. Metab Brain Dis. 2002. PMID: 12602508 Review. - Mineralocorticoid receptor antagonists as diuretics: Can congestive heart failure learn from liver failure?
Masoumi A, Ortiz F, Radhakrishnan J, Schrier RW, Colombo PC. Masoumi A, et al. Heart Fail Rev. 2015 May;20(3):283-90. doi: 10.1007/s10741-014-9467-2. Heart Fail Rev. 2015. PMID: 25447845 Free PMC article. Review. - Hepatic and splanchnic nitric oxide activity in patients with cirrhosis.
Sarela AI, Mihaimeed FM, Batten JJ, Davidson BR, Mathie RT. Sarela AI, et al. Gut. 1999 May;44(5):749-53. doi: 10.1136/gut.44.5.749. Gut. 1999. PMID: 10205218 Free PMC article. - Effects of nitric oxide inhibition by methylene blue in cirrhotic patients with ascites.
Kalambokis G, Economou M, Fotopoulos A, Bokharhii JA, Christos P, Paraskevi K, Konstantinos P, Katsaraki A, Tsianos EV. Kalambokis G, et al. Dig Dis Sci. 2005 Oct;50(10):1771-7. doi: 10.1007/s10620-005-2935-8. Dig Dis Sci. 2005. PMID: 16187171 Clinical Trial. - Enhanced urinary excretion of cGMP in liver cirrhosis. Relationship to hemodynamic changes, neurohormonal activation, and urinary sodium excretion.
Fernández-Rodriguez CM, Prieto J, Quiroga J, Zozaya JM, Andrade A, Rodriguez-Ortigosa C. Fernández-Rodriguez CM, et al. Dig Dis Sci. 1997 Jul;42(7):1416-20. doi: 10.1023/a:1018846122586. Dig Dis Sci. 1997. PMID: 9246039
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical